Australia's largest stock trading and investment forum Australia's #1 stock forum

OSP

0.00%

20.0¢ osprey medical inc

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-110

First 110 Last

Share
Profile

Follow
Tian8824

1,983 Posts.

118

18/02/22

00:11

Post #: 59649951
Share

Originally posted by Tian8824: ↑

The more extreme the volatility now, the more extreme the volatility later.

About 18 months ago, OSP 6x to 6 dollars on good volume in a week and speeding ticket from ASX. Not saying it will happen again, but that beach guy was spot on. Needs positive announcements and FDA approvals to get market traction.

Now if you invest 100k in telstra, and it drops 10%, it’s the same as if you bought 10k OSP and it drops to zero. Which scenario is more likely? Which investment decision will yield a greater return in the long run? The answer is OBVIOUS.

You can say if Telstra drop 10% some time after your purchase doesn’t count because you haven’t sold. But you have still already lost that 10% bc you could have bought it 10% cheaper.

However every 10% that OSP goes down, you are playing with fire. Because it is already so cheap.

Just imagine it is 2017, you read the fundie report and you are about to hit the buy button, BUT a Genie stopped you from buying OSP at 80 dollars. Transported you 5 years to the future. It’s 200x cheaper. You can buy 200x as much shares for the same money and same risk. You’ve missed all the drama with failed sales and Coronavirus. Maybe your friend even made 2000x in LTR.

There are only 2 reasons why people are selling. They can’t afford to lose more or they can’t afford to lose full stop long or short term. Then you shouldn’t be investing.

I think beach boy has been impartial and exceptional in his analysis. But he is just a tad too careful.

The risk lies in how much you invest as opposed to what you invest in. Even if you bought OSP at 80 bucks, now it’s 200x down, you can only lose less than 80 bucks. If you reinvest 800 at the current new price, you have resolved both your missed opportunity problem and your average entry price problem.

You might think I’m just a pumper. Actually I am trying to help everyone. Even the buying, I have only targeted big fundie sell orders bc I know if I buy off them, it’s for tax loss purposes and I believe they will buy back at a lower price. So win win for everybody. If I bought off a retail, they have lost so much and they are probably not selling for tax purposes, they have just lost. And I don’t think they will buy back. And I don’t want them to sell. Because there’s not much they can lose, but if the stock becomes 1 Billion market cap, it’s like a lost lottery ticket or Bitcoin thrown in the trash…

Expand

OSP is a perfect example of how hard it is to buy the bottom.

But you have seen nothing yet.

You try selling at the top. No missed investment opportunity is a missed opportunity because it’s always so easy in hindsight. You TRY selling at the top! Bitcoin or any asset.

In the scenario the company does 100x to 1 Billion market cap. Everybody currently holding would be gone by then.

So the payoff is only real if you hold. The smaller your investment, the lower your risk, but also the better your chances of holding long term.

Last edited by Tian8824: 18/02/22

OSP Price at posting: 41.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 110 more messages in this thread...

First 110 Last

Add OSP (ASX) to my watchlist

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-110

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News